| Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue | Frank Vinluan | 09/09/20 | National |
| Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest | Frank Vinluan | 09/08/20 | San Francisco |
| FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures | Frank Vinluan | 09/05/20 | Boston |
| Q&A: BIO CEO Michelle McMurray-Heath Outlines Diversity Goals | Mandy Jackson | 09/05/20 | National |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally | Frank Vinluan | 09/03/20 | Boston |
| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| New Podcast and Special Report Explore How AI Is Revolutionizing Drug Discovery and Development | Editors | 09/02/20 | National |
| Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% | Frank Vinluan | 09/01/20 | New York |
| Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
| Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday | Editors | 08/31/20 | Boston |
| Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal | Frank Vinluan | 08/31/20 | San Francisco |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests | Frank Vinluan | 08/27/20 | Seattle |
| National Xconomy Awards Digital Ceremony Complimentary Tickets Now Available | Editors | 08/27/20 | National |
| Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases | Frank Vinluan | 08/26/20 | Boston |
| FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines | Sarah de Crescenzo | 08/24/20 | National |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts | Sarah de Crescenzo | 08/20/20 | National |
| FDA Rejects BioMarin Hemophilia Gene Therapy, Asks for More Data | Sarah de Crescenzo | 08/19/20 | National |
| J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout | Frank Vinluan | 08/19/20 | New York |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| Sanofi Reaches $3.68B Deal to Buy Principia and Partnered MS Drug | Frank Vinluan | 08/17/20 | Europe |
| Advisory Body Backs MesoBlast Therapy for Transplant Complication | Sarah de Crescenzo | 08/14/20 | New York |
| CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears | Frank Vinluan | 08/14/20 | Europe |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
| Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy | Frank Vinluan | 08/11/20 | Europe |
